Literature DB >> 19738016

ATP synthase inhibition of Mycobacterium avium is not bactericidal.

Nacer Lounis1, Tom Gevers, Joke Van den Berg, Luc Vranckx, Koen Andries.   

Abstract

The efficacy of ATP synthase inhibitor TMC207 was assessed in early and late Mycobacterium avium infections in mice. In contrast to what was earlier observed for M. tuberculosis, a bacteriostatic effect was obtained. In vitro, the minimal bactericidal concentration (MBC)/MIC ratio was very high. The MBC was more relevant for assessment of pharmacokinetic/pharmacodynamic relationships than the MIC.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19738016      PMCID： PMC2772307          DOI： 10.1128/AAC.00689-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Medical management of pulmonary disease caused by Mycobacterium avium complex.

Authors:  Michael D Iseman
Journal:  Clin Chest Med       Date:  2002-09       Impact factor: 2.878

2.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Authors:  Andreas H Diacon; Alexander Pym; Martin Grobusch; Ramonde Patientia; Roxana Rustomjee; Liesl Page-Shipp; Christoffel Pistorius; Rene Krause; Mampedi Bogoshi; Gavin Churchyard; Amour Venter; Jenny Allen; Juan Carlos Palomino; Tine De Marez; Rolf P G van Heeswijk; Nacer Lounis; Paul Meyvisch; Johan Verbeeck; Wim Parys; Karel de Beule; Koen Andries; David F Mc Neeley
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

3.  Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice.

Authors:  C B Inderlied; P T Kolonoski; M Wu; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

4.  Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations.

Authors:  J H Huang; P N Kao; V Adi; S J Ruoss
Journal:  Chest       Date:  1999-04       Impact factor: 9.410

5.  In vitro and in vivo activities of clarithromycin against Mycobacterium avium.

Authors:  P B Fernandes; D J Hardy; D McDaniel; C W Hanson; R N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

6.  In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice.

Authors:  P R Gangadharam; V K Perumal; N R Podapati; L Kesavalu; M D Iseman
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

7.  Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model.

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

8.  Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases.

Authors:  D Y Rosenzweig
Journal:  Chest       Date:  1979-02       Impact factor: 9.410

9.  Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model.

Authors:  N Lounis; B Ji; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

10.  Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice.

Authors:  L Struillou; Y Cohen; N Lounis; G Bertrand; J Grosset; J L Vildé; J J Pocidalo; C Perronne
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191
View more
  19 in total

Review 1.  TMC207: the first compound of a new class of potent anti-tuberculosis drugs.

Authors:  Alberto Matteelli; Anna Cc Carvalho; Kelly E Dooley; Afranio Kritski
Journal:  Future Microbiol       Date:  2010-06       Impact factor: 3.165

2.  In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 3.  Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis.

Authors:  Mageshwaran Lakshmanan; Alphienes Stanley Xavier
Journal:  J Young Pharm       Date:  2013-12-30

4.  Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease.

Authors:  David C Alexander; Ravikiran Vasireddy; Sruthi Vasireddy; Julie V Philley; Barbara A Brown-Elliott; Benjamin J Perry; David E Griffith; Jeana L Benwill; Andrew D S Cameron; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2016-12-07       Impact factor: 5.948

5.  Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish.

Authors:  Christian Dupont; Albertus Viljoen; Sangeeta Thomas; Françoise Roquet-Banères; Jean-Louis Herrmann; Kevin Pethe; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 6.  Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria.

Authors:  Gregory M Cook; Kiel Hards; Catherine Vilchèze; Travis Hartman; Michael Berney
Journal:  Microbiol Spectr       Date:  2014-06

7.  In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.

Authors:  Barbara A Brown-Elliott; Julie V Philley; David E Griffith; Foram Thakkar; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 8.  Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?

Authors:  Stephen K Field
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091

9.  Mycobacterial Membrane Proteins QcrB and AtpE: Roles in Energetics, Antibiotic Targets, and Associated Mechanisms of Resistance.

Authors:  Luke Bown; Santosh K Srivastava; Brandon M Piercey; Clarissa K McIsaac; Kapil Tahlan
Journal:  J Membr Biol       Date:  2017-11-02       Impact factor: 1.843

Review 10.  NTM drug discovery: status, gaps and the way forward.

Authors:  Mu-Lu Wu; Dinah B Aziz; Véronique Dartois; Thomas Dick
Journal:  Drug Discov Today       Date:  2018-04-07       Impact factor: 7.851
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.